MODERN SURGICAL TECHNIQUES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5180Keywords:
Benign Prostate Hyperplasia, Lower Urinary Tract Symptoms, Minimally Invasive Surgical Therapies, Endoscopic Surgery, Systematic ReviewAbstract
Aims: To systematically review randomized evidence on modern minimally invasive and endoscopic techniques for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), focusing on clinical efficacy, safety, perioperative outcomes, preservation of sexual/ejaculatory function, and durability compared with TURP or sham.
Methods: We conducted a systematic PubMed search (2020–2025) using predefined terms for BPH surgery and randomized controlled trials. Main findings from eligible articles were summarized.
Results: The review identified 41 randomized controlled trials evaluating nine modern techniques (endoscopic enucleation, laser vaporization, Aquablation, Rezūm water vapor thermal therapy, prostatic urethral lift/PUL, transperineal laser ablation/TPLA, temporary nitinol device/iTind, drug-coated balloon/Optilume, and prostatic artery embolisation/PAE), comprising thousands of men with moderate-to-severe LUTS. Endoscopic enucleation and Aquablation showed durable, TURP-like or superior improvements in IPSS, QoL, Qmax, and PVR, particularly in large prostates (>80 mL), with better perioperative outcomes. Minimally invasive surgical therapies (MISTs) provided meaningful symptom relief and excellent preservation of sexual/ejaculatory function, while PAE had lower objective efficacy and higher reintervention rates. Serious complications were uncommon across all techniques.
Conclusions: Current evidence supports these modern techniques as valuable alternatives to TURP, enabling individualized treatment based on prostate volume and patient priorities for sexual function, recovery, and durability. However, heterogeneity in follow-up duration, variable prostate-size criteria, and the limited number of large head-to-head trials restrict definitive conclusions. Further adequately powered, long-term randomized studies are needed to better define the optimal role of each modality in clinical practice.
References
Jiang, B., et al. (2024). Safety and efficacy of transurethral holmium laser enucleation of the prostate versus bipolar transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: A prospective randomized controlled trial. Langenbeck’s Archives of Surgery, 409(1), 313. https://doi.org/10.1007/s00423-024-03499-2
Fuschi, A., et al. (2022). B-TURP versus HoLEP: Peri-operative outcomes and complications in frail elderly (>75 y.o.) patients: A prospective randomized study. Biomedicines, 10(12), 3212. https://doi.org/10.3390/biomedicines10123212
Lin, D., et al. (2025). 1470 nm diode laser enucleation versus bipolar transurethral resection of the prostate for the surgical management of benign prostatic hyperplasia: A randomized comparison. Lasers in Medical Science, 40(1), 226. https://doi.org/10.1007/s10103-025-04478-9
Zhang, J., et al. (2020). Holmium laser enucleation of the prostate versus thulium laser enucleation of the prostate for the treatment of large-volume prostates >80 ml: 18-month follow-up results. World Journal of Urology, 38(6), 1555–1562. https://doi.org/10.1007/s00345-019-02945-x
Bozzini, G., et al. (2021). A prospective multicenter randomized comparison between holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP). World Journal of Urology, 39(7), 2375–2382. https://doi.org/10.1007/s00345-020-03468-6
Shoma, A. M., et al. (2023). A randomized trial of holmium laser vs. thulium laser vs. bipolar enucleation of large prostate glands. BJU International, 132(6), 686–695. https://doi.org/10.1111/bju.16174
Romero Otero, J., et al. (2024). Prospective randomized multicenter study to evaluate holmium vs. new thulium fiber laser for prostate enucleation. Minerva Urology and Nephrology, 76(4), 491–498. https://doi.org/10.23736/S2724-6051.24.05706-9
Enikeev, D., et al. (2022). Randomized prospective trial of the severity of irritative symptoms after HoLEP vs. ThuFLEP. World Journal of Urology, 40(8), 2047–2053. https://doi.org/10.1007/s00345-022-04046-8
Bozzini, G., et al. (2023). Thulium: YAG vs. continuous-wave thulium fiber laser enucleation of the prostate: Do potential advantages of thulium fiber lasers translate into relevant clinical differences? World Journal of Urology, 41(1), 143–150. https://doi.org/10.1007/s00345-022-04201-1
Bhandarkar, A., & Patel, D. (2022). Comparison of holmium laser enucleation of the prostate with bipolar plasmakinetic enucleation of the prostate: A randomized, prospective controlled trial at midterm follow-up. Journal of Endourology, 36(12), 1567–1574. https://doi.org/10.1089/end.2022.0449
Wei, Z., et al. (2021). Plasma kinetic enucleation vs. holmium laser enucleation for treating benign prostatic hyperplasia: A randomized controlled trial with a 3-year follow-up. Journal of Endourology, 35(10), 1533–1540. https://doi.org/10.1089/end.2021.0086
Habib, E., et al. (2020). Holmium laser enucleation vs. bipolar plasmakinetic enucleation of a large volume benign prostatic hyperplasia: A randomized controlled trial. Journal of Endourology, 34(3), 330–338. https://doi.org/10.1089/end.2019.0707
Morsy, S., et al. (2024). Comparing surgical techniques: ThuLEP and transurethral BPEP for prostate over 80 grams: Intraoperative and postoperative results: A prospective randomized trial. Arab Journal of Urology, 23(1), 1–7. https://doi.org/10.1080/20905998.2024.2395594
Hashim, H., Worthington, J., Abrams, P., Young, G., Taylor, H., Noble, S. M., Brookes, S. T., Cotterill, N., Page, T., Swami, K. S., Lane, J. A., & UNBLOCS Trial Group. (2020). Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): A randomised controlled trial. Lancet, 396(10243), 50–61. https://doi.org/10.1016/S0140-6736(20)30537-7
Worthington, J., Taylor, H., Abrams, P., Brookes, S. T., Cotterill, N., Noble, S. M., Page, T., Swami, K. S., Lane, J. A., & Hashim, H. (2017). A randomised controlled trial to determine the clinical and cost effectiveness of thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP) in the National Health Service (NHS): The UNBLOCS trial: A study protocol for a randomised controlled trial. Trials, 18(1), 179. https://doi.org/10.1186/s13063-017-1916-5
Worthington, J., Lane, J. A., Taylor, H., Young, G., Noble, S. M., Abrams, P., Ahern, A., Brookes, S. T., Cotterill, N., Johnson, L., Khan, R., Fernandez, A. M., Page, T., Swami, S., & Hashim, H. (2020). Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: The UNBLOCS RCT. Health Technology Assessment, 24(41), 1–96. https://doi.org/10.3310/hta24410
Kotsiris, D., et al. (2023). Outcomes of thulium prostatectomy with “Oyster technique” versus transurethral prostatectomy (TURP): A randomized control trial. World Journal of Urology, 41(9), 2473–2479. https://doi.org/10.1007/s00345-023-04510-z
Shoji, S., et al. (2020). Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12 months: A prospective randomized study. International Journal of Urology, 27(11), 974–980. https://doi.org/10.1111/iju.14341
Okada, T., et al. (2022). A prospective, single-center, randomized clinical trial to evaluate the efficacy of three types of laser vaporization surgeries using a 180-W GreenLight XPS laser, a 300-W diode laser, and a 200-W thulium laser for the treatment of benign prostatic hyperplasia. Lower Urinary Tract Symptoms, 14(5), 373–379. https://doi.org/10.1111/luts.12453
Kobayashi, T., et al. (2021). GreenLight HPS laser 120 W vs. diode laser 300 W vaporization of the prostate for the treatment of benign prostatic hyperplasia in Japanese patients: A prospective, single-center, randomized clinical trial. Lower Urinary Tract Symptoms, 13(1), 31–37. https://doi.org/10.1111/luts.12324
Kini, M., et al. (2020). Ejaculatory hood-sparing photoselective vaporization of the prostate vs. bipolar button plasma vaporization of the prostate in the surgical management of benign prostatic hyperplasia. Journal of Endourology, 34(3), 322–329. https://doi.org/10.1089/end.2019.0558
Elmansy, H., et al. (2023). Holmium laser Xpeeda vaporization vs. GreenLight XPS vaporization of the prostate for benign prostatic obstruction: 1-year results from a randomized controlled clinical study. Journal of Endourology, 37(6), 706–712. https://doi.org/10.1089/end.2022.0727
Gilling, P. J., et al. (2022). Five-year outcomes for Aquablation therapy compared to TURP: Results from a double-blind, randomized trial in men with LUTS due to BPH. The Canadian Journal of Urology, 29(1), 10960–10968.
Gilling, P., et al. (2020). Three-year outcomes after Aquablation therapy compared to TURP: Results from a blinded randomized trial. The Canadian Journal of Urology, 27(1), 10072–10079.
Gilling, P., et al. (2019). Two-year outcomes after Aquablation compared to TURP: Efficacy and ejaculatory improvements sustained. Advances in Therapy, 36(6), 1326–1336. https://doi.org/10.1007/s12325-019-00952-3
Oumedjbeur, K., et al. (2023). Aquablation versus TURP: 5-year outcomes of the WATER randomized clinical trial for prostate volumes 50–80 mL. The Canadian Journal of Urology, 30(5), 11650–11658.
McVary, K. T., et al. (2021). Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Urology, 206(3), 715–724. https://doi.org/10.1097/JU.0000000000001778
Roehrborn, C. G., et al. (2017). Convective thermal therapy: Durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. The Journal of Urology, 197(6), 1507–1516. https://doi.org/10.1016/j.juro.2016.12.045
McVary, K. T., et al. (2016). Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Randomized controlled study. The Journal of Sexual Medicine, 13(6), 924–933. https://doi.org/10.1016/j.jsxm.2016.03.372
McVary, K. T., et al. (2016). Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Urology, 195(5), 1529–1538. https://doi.org/10.1016/j.juro.2015.10.181
Zucchi, A., et al. (2025). Preserving erectile and ejaculatory function in patients undergoing minimally invasive techniques: The first randomized clinical trial comparing convective water vapor ablation and transperineal laser ablation. The Journal of Sexual Medicine, 22(8), 1447–1454. https://doi.org/10.1093/jsxmed/qdaf150
Samir, M., et al. (2024). Two-year follow-up comparing Rezūm therapy versus bipolar transurethral resection of the prostate for treating benign prostatic hyperplasia: A prospective randomized study. International Journal of Urology, 31(5), 545–550. https://doi.org/10.1111/iju.15410
Sheba, M., et al. (2025). Randomised controlled trial comparing safety and efficacy of Urolift to monopolar TURP. Urologia, 92(1), 59–64. https://doi.org/10.1177/03915603241277905
Bertolo, R., et al. (2023). Ejaculatory function following transperineal laser ablation vs. TURP for benign prostatic obstruction: A randomized trial. BJU International, 132(1), 100–108. https://doi.org/10.1111/bju.16008
Elterman, D., et al. (2023). An evaluation of sexual function in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia in men treated with the temporarily implanted nitinol device. Journal of Endourology, 37(1), 74–79. https://doi.org/10.1089/end.2022.0226
Chughtai, B., et al. (2021). The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A multicenter, randomized, controlled trial. Urology, 153, 270–276. https://doi.org/10.1016/j.urology.2020.12.022
Kaplan, S. A., et al. (2023). The PINNACLE study: A double-blind, randomized, sham-controlled study evaluating the Optilume BPH catheter system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Urology, 210(3), 500–509. https://doi.org/10.1097/JU.0000000000003568
Kaplan, S. A., et al. (2024). Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE study). Prostate Cancer and Prostatic Diseases, 27(3), 531–536. https://doi.org/10.1038/s41391-024-00833-z
Copelan, O., et al. (2025). Preservation of sexual function with Optilume: A novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Sexual Medicine, 22(3), 446–453. https://doi.org/10.1093/jsxmed/qdae206
Abt, D., et al. (2021). Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial. European Urology, 80(1), 34–42. https://doi.org/10.1016/j.eururo.2021.02.008
Müllhaupt, G., et al. (2024). Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic obstruction: 5-year outcomes of a randomised, open-label, noninferiority trial. European Urology Focus, 10(5), 788–795. https://doi.org/10.1016/j.euf.2024.03.001
GBD 2019 Benign Prostatic Hyperplasia Collaborators. (2022). The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longevity, 3(11), e754–e776. https://doi.org/10.1016/S2666-7568(22)00213-6
Rojanasarot, S., Cutone, B., Bhattacharyya, S., DeRouen, K., & Miller, L. E. (2022). Long-term risk of surgery following first diagnosis of benign prostatic hyperplasia in middle-aged men. Cureus, 14(1), Article e20961. https://doi.org/10.7759/cureus.20961
Manfredi, C., Ditonno, F., Franco, A., Bologna, E., et al. (2024). Benign prostatic hyperplasia surgery: A contemporary ten-year analysis of usage trends and costs from a large US database. Journal of Urology, 211(Suppl. 5), e126. https://doi.org/10.1097/01.JU.0001008920.55771.18.02
European Association of Urology. (2024). EAU guidelines. EAU Guidelines Office.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Adam Andrzejewski, Dominika Raether, Dominika Julia Kozdroń, Michalina Weronika Nieścioruk, Paulina Szczepańska, Jacek Kowalski, Dominika Dutkiewicz, Alia Echtay Yarbou, Rami Mallah
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
